1. Home
  2. NUVL

as 04-01-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

;SMA (50)$78.24EMA (200)$80.77O: $70.82 H: $72.59 L: $67.80 C: $68.00 −2.82 (−3.98%)Elder Ray −2.45, −7.24
Founded: 2017 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 5.6B IPO Year: 2021
Target Price: $113.10 AVG Volume (30 days): 601.6K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.93 EPS Growth: N/A
52 Week Low/High: $61.80 - $113.51 Next Earning Date: 05-08-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

NUVL Daily Stock ML Predictions

SELLHOLDBUYas of 11 hours ago

Stock Insider Trading Activity of Nuvalent Inc. (NUVL)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Noci Darlene NUVL Chief Development Officer Mar 27 '25 Sell $73.37 4,000 $292,468.00 48,034
Porter James Richard NUVL President and CEO Mar 17 '25 Sell $76.06 27,000 $2,048,561.73 266,026
Noci Darlene NUVL Chief Development Officer Mar 6 '25 Sell $71.89 34,000 $2,443,578.02 48,034
Shair Matthew NUVL Director Feb 24 '25 Sell $78.38 2,000 $156,863.60 218,206
Porter James Richard NUVL President and CEO Feb 18 '25 Sell $78.73 27,000 $2,118,336.00 266,026
Shair Matthew NUVL Director Jan 27 '25 Sell $83.51 2,000 $165,575.90 218,206
Porter James Richard NUVL President and CEO Jan 15 '25 Sell $76.10 27,000 $2,051,777.37 266,026
Miller Deborah Ann NUVL Chief Legal Officer Jan 6 '25 Sell $79.38 2,964 $236,182.46 51,200
Noci Darlene NUVL Chief Development Officer Jan 6 '25 Sell $79.38 4,016 $320,009.01 48,034
Balcom Alexandra NUVL Chief Financial Officer Jan 6 '25 Sell $79.38 4,016 $320,009.01 63,907

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use